Innovative approach opens the door to COVID nanobody therapies

COVID is not yet under control. Despite a bevy of vaccines, monoclonal antibodies, and antivirals, the virus continues to mutate and elude us. One solution that scientists have been exploring since the early days of the pandemic ...

A new control system for synthetic genes

Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.

Molecular makeover makes wimpy antibody a SARS-CoV-2 tackler

Like the Roadrunner outwitting Wile E. Coyote, SARS-CoV-2 (the infectious virus responsible for COVID-19) keeps mutating, generating new variants that can slip from the grip of a well-trained immune system or a well-aimed ...

FDA approves monoclonal antibody to treat arthritis in cats

Arthritis can keep a cat from doing many of the things that kitties love to do. But now there's hope: The first treatment to ease arthritis pain in cats has been approved by the U.S. Food and Drug Administration.

Study rewrites dogma of adenovirus infection and double-stranded RNA

Challenging the dogma of what scientists thought they understood about DNA viruses, a team of researchers led by Children's Hospital of Philadelphia (CHOP) has shown that adenovirus uses its own efficient RNA splicing mechanisms ...

page 1 from 7

Monoclonal antibodies

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are identical because they are produced by one type of immune cell that are all clones of a single parent cell. Given almost any substance, it is possible to create monoclonal antibodies that specifically bind to that substance; they can then serve to detect or purify that substance. This has become an important tool in biochemistry, molecular biology and medicine. When used as medications, the generic drug name ends in -mab (see "Nomenclature of monoclonal antibodies").

This text uses material from Wikipedia, licensed under CC BY-SA